Evidence map›Paper›PMID 26946532›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2016

Original Research: Generation of non-deletional hereditary persistence of fetal hemoglobin β-globin locus yeast artificial chromosome transgenic mouse models: -175 Black HPFH and -195 Brazilian HPFH.

Carolina A Braghini, Flavia C Costa, Halyna Fedosyuk, Renee Y Neades, Lesya V Novikova, Matthew P Parker, Robert D Winefield, Kenneth R Peterson

Open access · greenAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Sickle cell disease severity: an introduction.Experimental biology and medicine (Maywood, N.J.) · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Carolina A BraghiniDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160 USA Hematology and Hemotherapy Center, University of Campinas, Sao Paulo, SP 13083, Brazil.
Flavia C CostaIntelligeneDX, Olathe, KS 66061, USA.
Halyna FedosyukDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160 USA.
Renee Y NeadesDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160 USA.
Lesya V NovikovaDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160 USA.
Matthew P ParkerDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160 USA.
Robert D WinefieldAnalytical Core Laboratory, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Kenneth R PetersonDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160 USA Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS 66160 USA kpeterson@kumc.edu.
University of Kansas Medical Center · USIntel (United States) · USUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

THE ROLE OF HUMAN PXR IN ANTI-TUBERCULOSIS DRUG-INDUCED LIVER INJURYP20RR021940 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI COPPLE, BRYAN L · 2006 to 2011
$12.1M
Nuclear Receptors in Liver Health and DiseaseP20GM103549 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2012 to 2015
$8.1M
Novel Approaches for the Control of Microbial PathogensP30GM103326 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LUTKENHAUS, JOSEPH F · 2012 to 2016
$5.3M
Mechanisms of HbF Activation by Non-deletional HPFHR01HL111264 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI PETERSON, KENNETH R · 2013 to 2016
$1.5M
Transactivation of Fetal HemoglobinR01DK081290 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI PETERSON, KENNETH R · 2008 to 2011
$1.4M
Regulation of Globin Gene Switching by O-GlcNAc Post-Translational ModificationR01DK100595 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI PETERSON, KENNETH R, SLAWSON, CHAD ERIC · 2014 to 2016
$788k
NCRR NIH HHS P20 RR021940NHLBI NIH HHS R01 HL111264NIDDK NIH HHS R01 DK081290NIDDK NIH HHS R01 DK100595NIGMS NIH HHS P20 GM103549NIGMS NIH HHS P30 GM103326
6 · The paper itself

Abstract

Fetal hemoglobin is a major genetic modifier of the phenotypic heterogeneity in patients with sickle cell disease and certain β-thalassemias. Normal levels of fetal hemoglobin postnatally are approximately 1% of total hemoglobin. Patients who have hereditary persistence of fetal hemoglobin, characterized by elevated synthesis of γ-globin in adulthood, show reduced disease pathophysiology. Hereditary persistence of fetal hemoglobin is caused by β-globin locus deletions (deletional hereditary persistence of fetal hemoglobin) or γ-globin gene promoter point mutations (non-deletional hereditary persistence of fetal hemoglobin). Current research has focused on elucidating the pathways involved in the maintenance/reactivation of γ-globin in adult life. To better understand these pathways, we generated new β-globin locus yeast artificial chromosome transgenic mice bearing the (A)γ-globin -175 T > C or -195 C > G hereditary persistence of fetal hemoglobin mutations to model naturally occurring hereditary persistence of fetal hemoglobin. Adult -175 and -195 mutant β-YAC mice displayed a hereditary persistence of fetal hemoglobin phenotype, as measured at the mRNA and protein levels. The molecular basis for these phenotypes was examined by chromatin immunoprecipitation of transcription factor/co-factor binding, including YY1, PAX1, TAL1, LMO2, and LDB1. In -175 HPFH versus wild-type samples, the occupancy of LMO2, TAL1 and LDB1 proteins was enriched in HPFH mice (5.8-fold, 5.2-fold and 2.7-fold, respectively), a result that concurs with a recent study in cell lines showing that these proteins form a complex with GATA-1 to mediate long-range interactions between the locus control region and the (A)γ-globin gene. Both hereditary persistence of fetal hemoglobin mutations result in a gain of (A)γ-globin activation, in contrast to other hereditary persistence of fetal hemoglobin mutations that result in a loss of repression. The mice provide additional tools to study γ-globin gene expression and may reveal new targets for selectively activating fetal hemoglobin.

Indexed as

Anemia, Sickle CellAnimalsbeta-GlobinsChromosomes, Artificial, YeastDisease Models, AnimalFetal HemoglobinFlow CytometryGene Expression RegulationMiceMice, TransgenicReal-Time Polymerase Chain Reactionbeta-GlobinsFetal Hemoglobinfetal hemoglobinGlobin genehemoglobinopathiesHPFHsickle cell diseasetransgenic mice

Identifiers

PMID26946532
PMCPMC4871743
OpenAlexW2293398762

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.